CJC-1295 + Ipamorelin

This preparation combines CJC-1295 and Ipamorelin. Of the blends in this catalogue it has the clearest mechanistic argument behind it, because the two compounds act on genuinely different receptors that happen to sit on the same cell.

The cell is the pituitary somatotroph, which makes and stores growth hormone. It carries two distinct receptors that prompt release. One responds to GHRH, the signal the hypothalamus sends as part of the growth axis; CJC-1295 is a stabilised version of that signal. The other responds to ghrelin, a hormone released by the stomach that reflects feeding state; Ipamorelin is a selective agonist for it.

Because the two receptors trigger release through different internal pathways, engaging both produces a larger response than either alone — not because one amplifies the other in a simple sense, but because the cell is being pushed by two independent mechanisms. This is a real interaction with a described basis, which is more than can be said for most combinations.

• Two independent pathways: The GHRH and ghrelin receptors signal through different internal routes to the same output. That independence is why the combination has a mechanistic argument rather than only a convention behind it.

• Selectivity on one side: Ipamorelin was chosen over earlier ghrelin-receptor peptides because it moves cortisol and prolactin far less. In a combination, a component with fewer off-target effects keeps the result interpretable.

• Mismatched durations: One component can persist for days in its long-acting form while the other clears in minutes. A combination of two very different durations is not a single intervention, and that matters for study design.

• Feedback stays intact: Both prompt the pituitary to release its own hormone rather than supplying hormone from outside, so the regulatory brakes above the gland continue to operate.

Growth hormone is released in pulses, and the size of a pulse depends on two things: how strongly the release signal arrives, and how much the opposing signal, somatostatin, is restraining the gland. GHRH-type compounds act on the first. Ghrelin-receptor compounds act through a separate pathway that also reduces the restraint, which is why the two together produce more than either does alone.

That mechanism is described in the published literature and is not merely asserted. It is also the reason this combination is the most defensible one in the catalogue: it rests on two known receptors on one identified cell type, rather than on an argument that two compounds address related aspects of a broad process.

The complication is duration. If the CJC-1295 component is the long-acting form, it is present continuously for days while the ghrelin-receptor component is cleared within hours. The combination is therefore not two signals arriving together — it is a sustained background with intermittent peaks on top of it, and since the natural system operates in pulses, that difference matters for what any result means.

The individual pharmacology is well supported. Both compounds have documented receptor activity, and that GHRH-type and ghrelin-receptor compounds produce a larger combined growth hormone response than either alone is an established finding from controlled studies, including in humans.

Neither compound is approved, there is no long-term human data for either, and the combination as supplied has not been evaluated in a controlled trial. It is supplied for laboratory research only. The measured endpoint throughout this literature is the hormone response itself, and this preparation is the standard way to produce it through both receptors at once.

CJC-1295 and Ipamorelin are supplied separately, and the CJC-1295 page explains the difference between its two forms — which is the variable most likely to affect what this preparation does.

Sermorelin is the unmodified GHRH fragment and the baseline comparator for the first component, while GHRP-2 and GHRP-6 are the less selective ghrelin-receptor peptides that the second was designed to improve upon. IGF-1 LR3 sits at the far end of the same chain — the effector the pituitary response eventually produces, supplied directly.